Drug intelligence / Profile preview

PTAP-009

Development stage: Preclinical
Lead developer: Peptron
Modality: Peptides
Administration: Subcutaneous

Overview

**PTAP-009** is a preclinical semaglutide-prolactin-releasing peptide fusion peptide being developed for type 2 diabetes mellitus. It is designed as a single covalent peptide entity that combines semaglutide-derived glucagon-like peptide 1 receptor agonism with a functional prolactin-releasing peptide component, aiming to maintain glycemic control while providing more durable appetite suppression. In rodent studies reported at the American Diabetes Association 2025 meeting, subcutaneous PTAP-009 produced blood-glucose lowering comparable to semaglutide and sustained appetite suppression for two weeks.

Targets

GPR10 (Prolactin-releasing peptide receptor)GLP1R (GLP-1R)

Beyond the preview

Go deeper on PTAP-009.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PTAP-009.

Explore the full profile